Zhejiang Yatai Pharmaceutical Co., Ltd. (SHE:002370)
China · Delayed Price · Currency is CNY 7.11
-0.03 (-0.42%)
Feb 4, 2026, 3:04 PM CST
SHE:002370 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 323.69 | 402.22 | 416.92 | 372.86 | 312.77 | 514.75 |
Other Revenue | 2.96 | 2.96 | 3.72 | 0.58 | 2.37 | 0.14 |
| 326.64 | 405.17 | 420.64 | 373.44 | 315.13 | 514.89 | |
Revenue Growth (YoY) | -23.25% | -3.68% | 12.64% | 18.50% | -38.80% | -27.27% |
Cost of Revenue | 230.4 | 284.42 | 288.54 | 247.23 | 210.24 | 261.7 |
Gross Profit | 96.24 | 120.75 | 132.1 | 126.22 | 104.89 | 253.18 |
Selling, General & Admin | 106.18 | 110.51 | 137.6 | 129.66 | 209.45 | 276.81 |
Research & Development | 16.02 | 14.64 | 21.79 | 26.14 | 28.62 | 37.35 |
Other Operating Expenses | 2.86 | 6.39 | 6.14 | 5.38 | 5.31 | 9.53 |
Operating Expenses | 125.35 | 132.12 | 165.11 | 162.21 | 236.02 | 333.56 |
Operating Income | -29.1 | -11.37 | -33.01 | -35.99 | -131.13 | -80.37 |
Interest Expense | -38.86 | -30.59 | -47.46 | -52.31 | -56.87 | -68.07 |
Interest & Investment Income | 199.23 | 65.12 | 16.08 | 11.78 | 15.99 | 12.35 |
Currency Exchange Gain (Loss) | -0.35 | -0.35 | - | - | - | - |
Other Non Operating Income (Expenses) | -2.43 | 0.55 | -1.07 | -0.97 | -0.03 | -0.04 |
EBT Excluding Unusual Items | 128.49 | 23.36 | -65.45 | -77.49 | -172.04 | -136.13 |
Gain (Loss) on Sale of Investments | 0.1 | 1.64 | 1.78 | -17.32 | -14.95 | 1.8 |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | 0.4 | 0.04 | 8.61 | 180.64 |
Asset Writedown | -3.32 | -0.16 | -4.71 | -40.27 | -22.06 | -0.87 |
Legal Settlements | -4.93 | -4.93 | 51.9 | -8.66 | -21.11 | -21.72 |
Other Unusual Items | 14.58 | 14.58 | 4.53 | 8.39 | -2.6 | 4.67 |
Pretax Income | 134.91 | 34.49 | -11.56 | -135.32 | -224.16 | 28.4 |
Income Tax Expense | 0.01 | 0.25 | 0.31 | -2.63 | 4.12 | 1.12 |
Earnings From Continuing Operations | 134.89 | 34.24 | -11.88 | -132.69 | -228.28 | 27.27 |
Net Income to Company | 134.89 | 34.24 | -11.88 | -132.69 | -228.28 | 27.27 |
Net Income | 134.89 | 34.24 | -11.88 | -132.69 | -228.28 | 27.27 |
Net Income to Common | 134.89 | 34.24 | -11.88 | -132.69 | -228.28 | 27.27 |
Shares Outstanding (Basic) | 777 | 685 | 594 | 531 | 531 | 545 |
Shares Outstanding (Diluted) | 777 | 685 | 594 | 531 | 531 | 545 |
Shares Change (YoY) | 20.19% | 15.32% | 11.89% | -0.02% | -2.68% | 1.68% |
EPS (Basic) | 0.17 | 0.05 | -0.02 | -0.25 | -0.43 | 0.05 |
EPS (Diluted) | 0.17 | 0.05 | -0.02 | -0.25 | -0.43 | 0.05 |
Free Cash Flow | 4.9 | 14.44 | 7.19 | -9.06 | -19.62 | -21.27 |
Free Cash Flow Per Share | 0.01 | 0.02 | 0.01 | -0.02 | -0.04 | -0.04 |
Gross Margin | 29.46% | 29.80% | 31.40% | 33.80% | 33.28% | 49.17% |
Operating Margin | -8.91% | -2.80% | -7.85% | -9.64% | -41.61% | -15.61% |
Profit Margin | 41.30% | 8.45% | -2.82% | -35.53% | -72.44% | 5.30% |
Free Cash Flow Margin | 1.50% | 3.56% | 1.71% | -2.43% | -6.23% | -4.13% |
EBITDA | -1.48 | 20.92 | 5.49 | 4.43 | -88.54 | -31.07 |
EBITDA Margin | -0.45% | 5.16% | 1.31% | 1.19% | -28.10% | -6.03% |
D&A For EBITDA | 27.63 | 32.29 | 38.51 | 40.42 | 42.59 | 49.3 |
EBIT | -29.1 | -11.37 | -33.01 | -35.99 | -131.13 | -80.37 |
EBIT Margin | -8.91% | -2.80% | -7.85% | -9.64% | -41.61% | -15.61% |
Effective Tax Rate | 0.01% | 0.71% | - | - | - | 3.96% |
Revenue as Reported | 326.64 | 405.17 | 420.64 | 373.44 | 315.13 | 514.89 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.